• HyperScribe™ Poly (A) Tailing Kit for IVT mRNA

  2026-09-24

  A practical guide to adding poly(A) tails to in-vitro-transcribed RNA for expression workflows, from pilot design through quality checks and troubleshooting. It also separates what tailing can improve from the contributions of capping, sequence design, and delivery—an important distinction when translating mRNA studies into bench assays.

• CD40–STING–TRAF2 Control of B Cells in ESCC

  2026-09-23

  A 2025 study links tertiary lymphoid structures with favorable outcomes in treatment-naïve esophageal squamous cell carcinoma and identifies IRF4 as a central B-cell activation signature. Its mechanistic experiments propose that CD40 and STING compete for TRAF2, reshaping non-canonical NF-κB signaling and promoting IRF4 expression.

• Triiodothyronine (T3) in Adipose Thermogenesis

  2026-09-22

  Use Triiodothyronine (T3) as a controlled endocrine perturbation to separate thyroid hormone receptor activation from the SETD7–Adcy7–Sirt1–CREB1 thermogenic axis. This workflow combines solvent-aware dosing, beige-adipocyte assays, and orthogonal metabolic readouts for metabolic disorder research.

• RNA Synthesis as a Lens on Viral Immune Evasion

  2026-09-22

  A translational perspective on how high-yield, modification-compatible SP6 transcription can help researchers investigate SARS-CoV-2 nucleocapsid-driven stress-granule biology, validate RNA-based assays, and plan scalable research workflows.

• Triiodothyronine (T3) in Adipose Thermogenesis

  2026-09-21

  Use Triiodothyronine (T3) as a controlled receptor-level perturbation to separate thyroid hormone effects from SETD7-dependent white adipose browning. This guide combines reagent handling, factorial cell workflows, metabolic readouts, and troubleshooting for more interpretable metabolic disorder research.

• Ko 143: Practical BCRP Inhibition Workflows

  2026-09-21

  Ko 143 is a selective BCRP inhibitor for separating transporter-driven drug efflux from general cytotoxicity, formulation, and metabolic effects. This workflow shows how to apply it in cell assays, Caco-2 transport studies, LC-MS/MS experiments, and carefully controlled in vivo BCRP inhibition studies.

• Nanoparticle mRNA Delivery Reverses Trastuzumab Resistance

  2026-09-20

  The reference study developed a tumor-microenvironment pH-responsive nanoparticle system for systemic delivery of PTEN mRNA to trastuzumab-resistant HER2-positive breast cancer models. Its central finding is that restoring PTEN expression can inhibit persistently active PI3K/Akt signaling, resensitize tumors to trastuzumab, and improve therapeutic control in preclinical settings.

• Recombinant Human Oncostatin M: Assay Guide

  2026-09-19

  A scenario-based guide to selecting, reconstituting, and interpreting Recombinant Human Oncostatin M in viability, proliferation, and cytotoxicity assays. It explains how SKU P1045 supports controlled dose-response design, practical handling, and evidence-based vendor evaluation.

• MG-262: A Temporal Map of Proteasome Signaling

  2026-09-19

  MG-262 enables controlled analysis of proteasome-dependent signaling in inflammatory epithelial models. This guide pairs Z-Leu-Leu-Leu-B(OH)2 with a time-resolved assay strategy grounded in cytokine and glucocorticoid regulation of BIRC2 and BIRC3.

• Dacomitinib and Ferroptosis: A Translational Roadmap

  2026-09-18

  Dacomitinib (PF-00299804) offers a powerful model for studying irreversible ErbB blockade, while METTL17 research reveals how mitochondrial translation can shape ferroptosis resistance. Together, these findings support a disciplined strategy for testing pathway, cell-death, and biomarker relationships without overstating an unvalidated drug–ferroptosis connection.

• Dasatinib (BMS-354825) Research Workflow

  2026-09-17

  Build a context-first workflow for connecting Dasatinib-mediated Src and Bcr-Abl inhibition with phosphorylation, cell-cycle, EMT, and metastatic phenotypes. This guide separates evidence-backed use cases from hypothesis-generating applications in prostate, pancreatic, leukemia, and thymic tumor research.

• HyperPFU™ high-fidelity DNA polymerase Guide

  2026-09-17

  HyperPFU™ high-fidelity DNA polymerase is intended for accurate PCR amplification of long, GC-rich, inhibited, or otherwise difficult DNA templates. It produces blunt-ended amplicons, so it is suitable for accuracy-focused cloning and sequencing workflows but not for protocols that require 3′-A overhangs or preformed sticky ends.

• SNAI1–PIK3R2/p-EphA2 Signaling in Thymic Tumors

  2026-09-16

  This 2024 study identifies SNAI1 as an oncogenic hub in thymic epithelial tumors and links it to epithelial–mesenchymal transition, cancer stem cell-like traits, and macrophage-state remodeling. Through integrated transcriptomic, epigenomic, proteomic, and functional assays, the authors define a SNAI1–PIK3R2/p-EphA2–GSK3β/β-catenin signaling axis that may inform therapeutic research in thymic carcinoma.

• Dasatinib Monohydrate for Reliable Cell Assays

  2026-09-16

  Learn how Dasatinib Monohydrate, SKU B5954, can support more interpretable viability, proliferation, and cytotoxicity experiments in kinase-driven models. This scenario-based guide covers formulation, controls, dose design, resistance studies, and practical product-selection criteria.

• NETs in CML: TKI Effects and Vascular Risk

  2026-09-15

  The reference study shows that neutrophil extracellular trap formation is elevated in chronic myeloid leukemia and is differentially altered by tyrosine kinase inhibitors. Its combination of patient-derived neutrophils with a BCR-ABL1-transduced differentiation model provides a mechanistic framework for studying how leukemia biology and TKI-associated vascular risk may intersect.

7956 records 1/531 page Next 12345 下5页 Last page